Effect of MS-153 on the development of behavioral sensitization to locomotion- and ataxia-inducing effects of phencyclidine

Psychopharmacology

Volumn 160, Issue 2, 2002, Pages 122-131

  Abekawa, T ^a   Honda, M ^a   Ito, K ^b   Inoue, T ^a   Koyama, T ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Ataxia; Behavioral sensitization; Glutamate; Locomotion; Phencyclidine

Indexed keywords

5 METHYL 1 NICOTINYL 2 PYRAZOLINE; GLUTAMIC ACID; MS 153; PHENCYCLIDINE; PYRAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; ATAXIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HYPERSENSITIVITY; INFRARED RADIATION; LOCOMOTION; MALE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RATING SCALE; SENSITIZATION; SENSOR; STEREOTYPY;

ANIMALS; ATAXIA; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; INJECTIONS, INTRAPERITONEAL; LOCOMOTION; MALE; NEUROPROTECTIVE AGENTS; NICOTINIC ACIDS; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPIC MOVEMENT DISORDER; TIME FACTORS;

EID: 0036197583     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-001-0958-1     Document Type: Article

References (43)

1. Effects of nitric oxide (NO) synthesis inhibition on the development of supersensitivity to stereotypy and locomotion stimulating effects of methamphetamine
2. Corticolimbic dopamine neuro-transmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine
3. Observations on the psychotomimetic effects of Sernyl
4. Recovery of neuropsychological functions during reduction in use of phencyclidine
5. The effect of 1-arylcyclohexyl-amine (Sernyl) on twelve normal volunteers
6. The psychiatric aspects of chronic phencyclidine use; a study of chronic PCP users
7. Evidence for multiple opiate receptor involvement in different phencyclidine-induced unconditioned behaviors in rats
8. Abnormalities of regional cerebral blood flow in patients with mental deterioration due to chronic schizophrenia
9. Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase
10. Recent advances in the phencyclidine model of schizophrenia
11. Prefrontal cortical involvement in phencyclidine-induced activation of mesolimbic dopamine system: Behavioral and neurochemical evidence
12. Neuropharmacology of phencyclidine: Basic mechanisms and therapeutic potential
13. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex
14. The pharmacology and neural circuitry of sensitization to psychostimulants
15. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801
16. DNQX blockade of amphetamine behavioral sensitization
17. Cerebroprotective effects of a novel pyrazoline derivative. MS-153, on focal ischemia in rats
18. Metabotropic glutamate receptors are necessary for sensitization by amphetamine
19. Effect of MS-153, in ischemic lesions in the rat middle cerebral artery occlusion model
20. Effects of the AMPA receptor antagonist NBQX on the development and expression of behavioral sensitization to cocaine and amphetamine
21. Study of a new schizophrenomimetic drug
22. The phencyclidine psychosis
23. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens
24. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
25. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
26. Phencyclidine-induced stereotyped behaviors in rats following specific neurotoxin lesions of the striatum
27. Effect of lesions in the striatum, nucleus accumbens and medial raphe on phencyclidine-induced stereotyped behaviors and hyperactivity in rats
28. Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine
29. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis
30. Competitive and non-competitive NMDA antagonists block sensitization to methamphetamine
31. Dramatic limbic and cortical effects mediated by high affinity PCP receptors
32. The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs - A review
33. The neuroprotective agent MS-153 stimulating glutamate uptake
34. Effects of chronic administration of phencyclidine on stereotyped and ataxic behaviors in the rat
35. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: A microdialysis and behavioral study
36. Development of both conditioning and sensitization of behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801
37. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats
38. Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex
39. Inhibitory effect of MS-153 on elevated brain glutamate level induced by rat middle cerebral artery occlusion
40. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
41. Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine
42. PET scan study of patients on phencyclidine
43. Phencyclidine-induced behavioral sensitization